Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016;44(D1):D877-81. doi:10.1093/nar/gkv1340.

Yi TM, Lander ES. Recognition of related proteins by iterative template refinement (ITR). Protein Sci. 1994;3(8):1315-28. doi:10.1002/pro.5560030818.

Harbison CT, Gordon B, Lee TI, et al. Transcriptional regulatory code of a eukaryotic genome. Nature. 2004;431(7004):99-104. doi:10.1038/nature02800.

1000 Genomes Project Consortium, Abecasis GR, Auton A, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56-65. doi:10.1038/nature11632.

Flavahan WA, Drier Y, Liau BB, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529(7584):110-4. doi:10.1038/nature16490.

Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-8. doi:10.1038/nature13297.

Dong CK, Urgaonkar S, Cortese JF, et al. Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors. Chem Biol. 2011;18(12):1602-10. doi:10.1016/j.chembiol.2011.09.016.

Saeed S, Quintin J, Kerstens HHD, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345(6204):1251086. doi:10.1126/science.1251086.

Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54-61. doi:10.1056/NEJMoa1508887.

Guilinger JP, Pattanayak V, Reyon D, et al. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods. 2014;11(4):429-35. doi:10.1038/nmeth.2845.